

Systematic Review

A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)

Hassen Mohammed ^{1,2,*}, Dan Duy Pham-Tran ², Zi Yi Michelle Yeoh ², Bing Wang ^{1,2}, Mark McMillan ^{1,2}, Prabha H. Andraweera ^{1,2} and Helen S. Marshall ^{1,2}

- ¹ Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, SA 5006, Australia
- ² Robinson Research Institute and Adelaide Medical School, the University of Adelaide, Adelaide, SA 5006, Australia
 - Correspondence: hassen.mohammed@adelaide.edu.au; Tel.: +61-8-8161-9157

Abstract: Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, and severe outcomes. We systematically searched literature up to 1 August 2022. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled vaccine effectiveness (VE). Overall, 28 studies were included representing 11 million individuals. The pooled VE against Omicron infection was 20.4% (95%CI: 12.1–28.7%) and 23.4% (95%CI: 13.5–33.3%) against symptomatic infection with variation based on vaccine type and age groups. VE sharply declined from 28.1% (95%CI: 19.1–37.1%) at three months to 3.9% (95%CI: -24.8–32.7%) at six months. Similar trends were observed for symptomatic Omicron infection. A booster dose restored protection against Omicron infection up to 51.1% (95%CI: 43.8–58.3%) and 57.3% (95%CI: 54.0–60.5%) against symptomatic infection within three months; however, this waned to 32.8% (95%CI: 16.8–48.7%) within six months. VE against severe Omicron infection following the primary course was 63.6% (95%CI: 57.5–69.7%) at three months, decreased to 49% (95%CI: 35.7–63.4%) within six months, and increased to 86% after the first or second booster dose.

Keywords: COVID-19; Omicron; vaccine effectiveness; COVID-19 vaccines; booster vaccination

1. Introduction

The Omicron variant (B.1.1.529) was reported to the World Health Organization (WHO) from South Africa in late November 2021 [1]. It was immediately designated as a variant of concern (VOC) [1]. Compared to pre-omicron variants, a number of mutations have been identified in the omicron variant, including multiple mutations in the receptor-binding domain of the spike protein associated with increased transmissibility and immune evasion after natural infection and vaccination [2–4]. The omicron variant has rapidly evolved into new sub-lineages or sub-variants: BA.1 (B.1.1.529.1), BA.2 (B.1.1.529.2), BA.3 (B.1.1.529.3), BA.4 (B.1.1.529.4), and BA.5 (B.1.1.529.5). As of 29 November 2022, BA.5, BA.2.75, BA.4.6 and XBB (a hybrid of two different Omicron BA.2 sub-variants) are Omicron sub-lineages being monitored by the WHO to investigate if these lineages may pose an additional threat to global public health [1].

Several studies have shown diminished neutralization of both Omicron variants by pre-Omicron convalescent sera and by sera of vaccinated individuals [4–6]. Recent studies have shown a reduction in COVID-19 vaccine effectiveness against the Omicron variant [7–11], affecting the current COVID-19 vaccination strategy. Recent social media analysis has



Citation: Mohammed, H.; Pham-Tran, D.D.; Yeoh, Z.Y.M.; Wang, B.; McMillan, M.; Andraweera, P.H.; Marshall, H.S. A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529). *Vaccines* 2023, *11*, 224. https:// doi.org/10.3390/vaccines11020224

Academic Editors: Angelos Hatzakis and Dimitrios Paraskevis

Received: 2 December 2022 Revised: 12 January 2023 Accepted: 14 January 2023 Published: 19 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). shown increased public vaccine hesitancy due to the potential lack of effectiveness of ancestral COVID-19 vaccines against the new VOCs [12].

Emerging data on high prevalence of asymptomatic infection, greater risk of reinfection, and reduced vaccine protection during the omicron-dominant period compared to the earlier VOC warrants further investigation on the effectiveness of current COVID-19 vaccines against the Omicron variant [7–11,13]. A systematic review and meta-analysis have recently been published to evaluate the effectiveness of the current COVID-19 vaccines against Omicron infection [14]. This meta-analysis included 15 studies and demonstrated that primary vaccination does not provide sufficient protection against symptomatic Omicron infection [14]. However, the systematic review included studies conducted in the early Omicron era with shorter-term follow up. The real-world long-term effectiveness and durability of protection conferred by primary COVID-19 vaccination course and booster doses against the Omicron variant is not precisely known. To summarize the existing evidence on the effectiveness and the duration of protection conferred by COVID-19 vaccines, data were synthesized from an ongoing systematic review [15]. This systematic review aimed to investigate the real-word effectiveness of primary and booster vaccination against SARS-CoV-2 infection and severe COVID-19 disease due to laboratory-confirmed SARS-CoV-2 Omicron variant. The review also aimed to evaluate the duration of protection following full vaccination and booster doses.

2. Methods

The systematic review drew data from an ongoing systematic review that aimed to synthesis and evaluate the vaccine effectiveness (VE) of COVID-19 vaccines at preventing SARS-CoV-2 infections and severe COVID-19 disease in real-world settings. The systematic review followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guideline and was registered in the Prospective Register of Systematic Reviews (PROSPERO registration ID: CRD42022291375) [15].

2.1. Search Strategy

Systematic literature searches were performed on MEDLINE, PubMed, Embase and Cochrane Database of Systematic Reviews website on or before 1 August 2022 with no language restrictions. WHO COVID-19 DATABASE, pre-print severs (medRxiv, bioRxiv) and grey literature were searched. For preprint studies with several versions available, the most recent update published up to 1 August 2022 was included. Reviews and their references are examined for inclusion. Medical subject headings with the following search keywords were used: SARS-CoV-2 OR COVID-19 AND Vaccine OR Vaccination AND OR Vaccine effectiveness. The methods have been previously described in detail in the ongoing systematic review protocol [15] and full search strategies are available in Supplementary Material S1.

2.2. Study Selection

Observational (non-randomized) studies including cohort studies (prospective or retrospective), cross-sectional studies, case control including test-negative design (TND), regression discontinuity design studies, post-licensure observational studies that investigated the effectiveness of COVID-19 vaccines against documented, symptomatic, severe COVID-19 disease (defined as hospitalization, ICU admission, intubation or mechanical ventilation, or death) were included. COVID-19 cases were defined as being due to the Omicron variant infection, based on S target–negative results on PCR or whole-genome sequencing. VE studies that evaluated effectiveness of the primary vaccine course and booster vaccination compared to no vaccination were included. Outcomes of interest were VE against Omicron infection of "any type" (i.e., studies did not indicate underlying symptoms), "symptomatic COVID-19", and "severe COVID-19" due to Omicron infection. We only included studies that evaluated VE \geq 14 days after the primary vaccination course, and \geq 7 days after the booster dose. No restrictions were applied to the age of participants, the types of vaccination, or the number of participants. Heterologous primary schedules were

considered. Studies that did not report VE data or did not use any confounder adjustment strategies were excluded.

All the relevant records were screened by title and abstract. The retrieval results were screened with the help of Endnote and duplicate studies were eliminated. Potentially relevant publications underwent full-text examination and disagreements on eligibility were solved through discussion. The full texts suitable for the quantitative synthesis were collected in an excel spreadsheet for data extraction.

2.3. Data Extraction

Data were extracted by three (H.M., D.D.P.-T. and Z.Y.M.Y.) independent reviewers to identify eligible studies that met pre-specified inclusion criteria. The following information: study design, year of publication, country, age, population type, type of vaccines, time period post primary series or booster doses and study follow-up period, were extracted from the eligible studies. VE data were stratified according to SARS-CoV-2 vaccination course, \geq 14 days after completion of the primary vaccination course and \geq 7 days after receiving the first or second booster doses. Within each subgroup, the vaccination course was classified according to the vaccine type or technology. Duration of effectiveness of SARS-CoV-2 vaccines was assessed in intervals of three, six, and longer than six months after the primary vaccination series, whereas for the booster vaccination, shorter time intervals were considered (seven or more days, within three months, three to six months) due to less follow-up time since introduction.

2.4. Quality Assessment

The Joanna Briggs Institute (JBI) tools [16] were used to assess risk of bias of the included studies (Supplementary Material S2).

2.5. Data Analysis

Descriptive statistics were used to summarize the characteristics of studies included in this review. VE was quantified as the risk reduction of any or severe Omicron infection, expressed as a percentage, compared to the unvaccinated group. VE estimates were derived from regression models (Logit, Poisson, and Cox regression models) and calculated as $(1 - IRR) \times 100$, where IRR = incidence rate ratio; $(1 - HR) \times 100$, where HR = Hazard ratio; $(1 - RR) \times 100$, where RR = Risk ratio; and $(1 - OR) \times 100$, where OR = Odds ratio is the ratio of the rate of COVID-19 in the vaccinated group to the corresponding rate in the unvaccinated group. The DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction was used to combine VE estimates. We used the I^2 test to quantify the heterogeneity between studies. I^2 values were defined as low (\leq 50%), moderate (50–75%), or high heterogeneity (>75%). To estimate the duration of protection following the primary vaccination series, we modeled days since completing the primary course as a continuous effect, allowing for nonlinearity by using restricted cubic splines. The analysis was carried out using Stata 17.

3. Results

3.1. Characteristics of Studies

The initial search generated 13,601 studies. After removing duplicates, screening titles and abstracts of 7710 potential studies, 909 studies were identified for full text review (Figure 1). After a full text review, 299 studies were included for the ongoing systematic review as of 1 August 2022. In total, 28 observational VE studies on confirmed Omicron cases (22 case-control [9–11,17–35] and six cohort studies [7,8,36–39]) were included in this metaanalysis. Overall, 17 studies [17–22,24–29,31,34,35,38,39] investigated VE of both primary and booster vaccination, nine primary vaccination course without boosters [7–9,11,23,32,36] and two evaluated VE of booster doses only [30,37]. A total of 238 different VE estimates against documented Omicron infection (n = 47), symptomatic (n = 95) and severe COVID-19 disease (n = 96) over different time periods were included in this meta-analysis. Of these, 47% (n = 112) were for primary vaccination series and 52.9% (n = 126) for booster doses. Of the total 238 VE estimates, 196 (82.2%) were calculated from odds ratio (OR), 29 (12.1%) from the hazard ratio (HR), 10 (4.2%) from incidence rate ratio (IRR) and three (1.2%) from risk ratio (RR).



Figure 1. PRISMA flow diagram for study selection.

The included studies had a total of sample size of 11.6 million individuals, and ranged from 1052 to 2,706,008 participants. The majority of the studies were carried out in USA (n = 12) [9,10,17,26,28–31,35–37,39] followed by the UK (n = 6) [11,25,32–34,38], Canada (n = 4) [19–21,24], Qatar (n = 2) [18,22], France (n = 1) [27], Denmark (n = 1) [7], South Africa

(n = 1) [23] and Chile (n = 1) [8] (Table 1). The majority of the included studies (n = 18)evaluated VE in adults \geq 18 years of age, while two were exclusively on the pediatric populations (5–12 years of age) [22,23], two on adolescents (12–17 years of age) [11,19], one middle age adults (40–64 years of age) [25] and two on older adults (\geq 60 years of age) [7,24]. Two studies [37] included high risk populations (patients under hemodialysis therapy). The primary vaccination course represents two doses of BNT162b2 (Pfizer–BioNTech), mRNA-1273 vaccines (Moderna), AZD1222 (ChAdOx1 nCoV-19, AstraZeneca), CoronaVac (Sinovac), or one dose of Ad26.COV2.S (Janssen) vaccines. Most booster studies investigated VE of a single mRNA-based booster dose following the primary vaccination course, and only one study reported VE of a third dose of the vector-based vaccine, AZD1222 [25]. One study evaluated the VE of a second booster dose of the mRNA-1273 vaccines following three doses of mRNA-based vaccines [24] (Table 1). The median follow-up period for booster dose was shorter (16.5 weeks, IQR: 8.5-24) compared to the primary vaccine course (44 weeks, IQR 24-48). The quality assessment of each study using the JBI critical appraisal checklist is listed in Supplementary Material S2. The majority of included VE studies accounted for key potential confounders that may have influenced both the receipt of COVID-19 vaccine and the occurrence of SARS-CoV-2 infection. The list of covariates used in final analyses of vaccine effectiveness (VE) estimates from the included primary studies is reported in Supplementary Material S3.

Study	Country	Study Design	Population/Age Group	Sample Size	Type of Primary Vaccines	Interval since Primary Series (Days)	Type of Booster Vaccines	Interval since Booster Dose (Days)	Outcomes	VE/100%
Adams et al. 2022 [17]	USA	Case- negative control	Hospitalized adults ≥18 years	3181	Ad26.COV2.S, mRNA- 1273, BNT162b2	14+	Ad26.COV2.S, mRNA- 1273, BNT162b2	7+	Hospitalization	1-OR
Altarawneh et al. 2022 [18]	Qatar	Case- negative control	Individuals, all ages	158,484	mRNA- 1273, BNT162b2	14+	mRNA- 1273, BNT162b2	7+	Symptomatic infection, hospitaliza- tion/death	1-OR
Buchan et al. 2022a [20]	Canada	Case- negative control	Adolescents 12–17 years	29,855	BNT162b2	7–59, 180+	BNT162b2	7+	Symptomatic infection, severe infection	1-OR
Buchan et al. 2022b [19]	Canada	Case- negative control	General population ≥18 years	134,435	BNT162b2	7–59, 180+, 240+	BNT162b2, mRNA- 1273	7+	Symptomatic infection, severe infection	1-OR
Carazo et al. 2022 [21]	Canada	Case- negative control	Healthcare workers aged 18–59	37,732	mRNA- 1273, BNT162b2	14+	mRNA- 1273, BNT162b2	14+	Documented infection, symptomatic infection	1-OR
Chemaitelly et al. 2022 [22]	Qatar	Case- negative control	General population ≥5 years	2,706,008	mRNA- 1273, BNT162b2	30–90, 30–182, 212+	mRNA- 1273, BNT162b2	14–30, 30+, 43+	Symptomatic infection, severe infection	1-OR
Collie et al. 2022 [23]	South Africa	Case- negative control	General population ≥5 years	211,610	BNT162b2	14+	NA	NA	Hospitalization	1-OR
Fowlkes et al. 2022 [36]	USA	Cohort	Children 5–11 years	1052	BNT162b2	14–149, 150+	NA	NA	Documented infection	1-OR
Grewal et al. 2022 [24]	Canada	Case- negative control	LTCF residents 60+ years	13,654	mRNA- 1273, BNT162b2	14+	mRNA- 1273, BNT162b2	7+, 14–84	Documented infection, symptomatic infection, hospitaliza- tion/death	1-OR
Hansen et al. 2021 [7]	Denmark	Cohort	Older adults 60+ years	41,684	mRNA- 1273, BNT162b2	15–44, 105–164	NA	NA	Documented infection	1-HR

Table 1. Characteristics of the studies included in the meta-analysis.

Time

Time

Table 1. Co

Study	Country	Study Design	Population/Age Group	Sample Size	Type of Primary Vaccines	Time Interval since Primary Series (Days)	Type of Booster Vaccines	Time Interval since Booster Dose (Days)	Outcomes	VE/100%
Jara et al. 2022 [8]	Chile	Cohort	Children 3–5 years	490,064	CoronaVac	14+	NA	NA	Documented infection, hos- pitalization, ICU admission	1-HR
Kim et al. 2022 [9]	USA	Case- negative control	General population ≥18 years	3847	mRNA- 1273, BNT162b2	14–14, 150	NA	NA	Symptomatic infection	1-RR
Kirsebom et al. 2022 [25]	UK	Case- negative control	759,450 Middle-Aged Adults 40–64 & 759,450 Older adults 65+ years	166,720	AZD1222	175+	AZD1222, BNT162b2	7+, 14–34, 70–104, 105+	Symptomatic infection, Hospitaliza- tion	1-OR
Lauring et al. 2022 [26]	USA	Case- negative control	General population ≥18 years	17,126	mRNA- 1273, BNT162b2	14+	mRNA- 1273, BNT162b2	7+	Hospitalization	1-OR
Lind et al. 2022 [10]	USA	Case- negative control	General population ≥5 years	130,073	mRNA- 1273, BNT162b2	14, 14–149, 150+	NA	NA	Documented infection	1-OR
Montez- Rath et al. 2022 [37]	USA	Cohort	Dialysis patients ≥18 years	3576	NA	NA	mRNA- 1273, BNT162b2	21+	Documented infection	1-RR
Powell et al. 2022 [11]	UK	Case- negative control	Adolescents 12–17 years	617,259	BNT162b2	14–34, 70+	NA	NA	Symptomatic infection	1-OR
Spensley et al. 2022 [38]	UK	Cohort	Haemodialysis patients ≥18 years	1121	BNT162b2, AZD1222	14+	AZD1222, BNT162b2	14+	Documented infection	1-HR
Suarez Castillo et al. 2022 [27]	France	Case- negative control	General population ≥18 years	761,744	BNT162b2, AZD1222	0–30, 180+	BNT162b2, AZD1222	8–14, 90+	Documented infection, hos- pitalization, ICU admission, Death	1-OR
Tartof et al. 2022a [28]	USA	Case- negative control	General population ≥18 years	11,123	BNT162b2,	7–90	BNT162b2	14–90, 90+	Hospitalization, ED admissions	1-OR 1-HR
Tartof et al. 2022b [29]	USA	Case- negative control	General population ≥18 years	65,813	BNT162b2	14–182, 182+	BNT162b2	7–90, 90+	Hospitalization, ED admissions	1-OR
Thompson et al. 2022 [30]	USA	Case- negative control	Hospitalized adults ≥18 years	31,0676	Not stated	Not stated	mRNA- 1273, BNT162b2	14+	Hospitalization, ED admissions	1-OR
Tseng et al. 2022 [31]	USA	Case- negative control	General population ≥18 years	109,662	mRNA- 1273	14+, 14–90, 270+	mRNA- 1273	14+, 14–60	Documented infection, hos- pitalization	1-OR
UKHSA 2022 [33]	UK	Case- negative control	General population ≥18 years	996,670	BNT162b2, AZD1222, mRNA- 1273	14–28, 140–168, 175+	NA	NA	Symptomatic infection	1-HR
UKHSA/And et al. 2022 [32]	drews UK	Case- negative control	General population ≥18 years	996,670	Not stated	Not stated	BNT162b2, AZD1222, mRNA- 1273	14–28, 29–53, 70+	Symptomatic infection	1-IRR
Willet et al. 2022 [34]	UK	Case- negative control	General population ≥18 years	11,077	mRNA- 1273, BNT162b2	14+	mRNA- 1273, BNT162b2	14+	Documented infection	1-OR
Yoon et al. 2022 [39]	USA	Cohort	Healthcare workers ≥18 years	3241	mRNA- 1273, BNT162b2	14+	mRNA- 1273	7+	Documented infection	1-HR
Young-Xu et al. 2022 [35]	USA	Case- negative control	Veterans ≥18 years	372,636	mRNA- 1273, BNT162b2	14+	mRNA- 1273, BNT162b2c	14+	Documented infection, hos- pitalization, death	1-OR

3.2. Vaccine Effectiveness

3.2.1. VE against Any Omicron Infection following Completion of the Primary Vaccination Course

A total of four studies (24 different VE estimates) [7,8,10,36] were included in the meta-analysis of primary vaccination series against Omicron infection. Two studies were conducted in the USA [10,36], one in Denmark [7] and one in Chile [8]. For all ages and vaccines, the pooled VE against any SARS-CoV-2 Omicron infection was 20.4% (95%CI: 12.1–28.7%, $I^2 = 96.4\%$). The pooled VE estimate within 3 months following the primary vaccination course was 28.1% (95 CI: 19.1-37.1%). The VE estimates varied based on vaccine type, for mRNA based; BNT162b2 38.1% (95%CI: 23.3–52.8%), mRNA-173, 27.8% (95%CI: 6.6–49.0%), BNT162b2 or mRNA-1273, 22.3 (95%CI: 8.6–36.0%) and for vector based; AZD1222, 9.4% (95%CI: -15.5-34.4%). The estimated VE for CoronaVac was 37.8% (95% CI: 36.1–39.6%, data from a single study) in children 3–5 years of age (Figure 2). As displayed on the scatter plot, VE against Omicron infection declined sharply approximately after 2 months (50–60 days) following the primary vaccination course (Figure S1). The pooled VE estimates decreased to 4.0% (95%CI -24.8-32.7%) within three to six months (only mRNAbased vaccines included). There were not enough time data points to estimate pooled VE against Omicron infection after six months (mRNA-1273; 5.9%, 95%CI: 0.60-11.2%, data from a single study) (Figure 2).

3.2.2. VE against Symptomatic Omicron Infection following Completion of the Primary Vaccination Course

A total of 10 studies (39 different VE estimates) were included in the meta-analysis of primary vaccination series against symptomatic Omicron infection conducted in the UK (n = 3) [11,25,32], Canada (n = 3) [19,20], Qatar (n = 2) [18,22], USA (n = 1) [9] and France (n = 1) [27]. The pooled VE estimate against symptomatic Omicron infection for all ages and vaccine types was 23.4% (95%CI: 13.5–33.3%, $I^2 = 99.6$ %). The pooled VE against symptomatic Omicron disease was 37.1% (95%CI: 26.9–47.2%) after the first three months, declining to 10.6% (95%CI: 4.6–16.5%) between three to six months to -4.3% (95%CI: -15.4-6.7%) after six months (Figure 3). VE against symptomatic Omicron infection had a similar reduction over time, rapidly declining around 40 days following the primary vaccination course, as shown on the scatter plot (Figure 4).

3.2.3. VE against Severe Omicron Infection following Completion of the Primary Vaccination Course

A total of 12 studies (49 different VE estimates) conducted in USA (n = 4) [17,28,29,31], Canada (*n* = 3) [19,20,24], Qatar (*n* = 2) [18,22], France (*n* = 1) [27], South Africa (*n* = 1) [23] and Chile (n = 1) [8] evaluated VE against severe Omicron infection. Severe COVID-19 was a composite outcome of hospitalization (59.1%), emergency department (14.2%), intubation or mechanical ventilation (14.2%), admission to the intensive care unit (ICU) (6.1%), or death (6.1%). Only two [27,35] studies evaluated the effectiveness of COVID-19 vaccines against death. Two studies [18,24] included death or hospitalization as a composite outcome of severe Omicron infection. Therefore, VE estimates against death were not pooled separately due to the low number of studies and insufficient data. The pooled VE against severe COVID-19 was 56.9% (95%CI: 51.4–62.5%, $I^2 = 84.4\%$) (Figure 5). VE against severe Omicron infection decreased from 63.6% (95%CI: 57.5–69.7%) at three months to 48.3% (95%CI: 39.0–57.6%) at six months following the primary vaccination series (Figure 5). VE remained stable after six months at 49.7% (95%CI: 35.7–63.7%), also shown on the scatter plot (Figure S2). The highest pooled VE estimates against severe Omicron disease were observed following two doses of mRNA-1273 within 3 months (72.5%, 95%CI: 55.7–89.3%, $I^2 = 59.7$).

Study	Age	Time (days)) Subvariant	Effect siz with 95%	e Cl		Weight (%)
AZD1222 Within 3 months		(,,,,,,,,,,,,					()
Spensley	≥18	14+	Omicron	-4.00 [-74.00.	66.001		1.13
Willet	≥18	14+	Omicron	11.40 [-15.30.	38,101	_	3.54
Heterogeneity: $T^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$				9.44 [-15.50.	34.391	-	
Test of $\theta_i = \theta_j$: Q(1) = 0.16, p = 0.69							
BNT162b2 Within 3 months							
Fowlkes	12-15	14+	Omicron	59.00 [32.00,	86.00]		3.51
Fowlkes	5-11	14-82	Omicron	31.00 [11.50,	50.50]		4.27
Hansen	≥60	15-44	Omicron	55.20 [30.10,	80.30]		3.70
Spensley	≥18	14+	Omicron	17.00 [-42.50,	76.50]		1.45
Willet	≥18	14+	Omicron	26.00 [14.75,	37.25]	-	5.06
Heterogeneity: T ² = 135.02, I ² = 52.17%, H ² = 2	.09			38.05 [23.28,	52.83]	•	
Test of $\theta_i = \theta_j$: Q(4) = 8.36, p = 0.08							
BNT162b2/mRNA-1273 Within 3 months							
Lind	≥5	14	BA.1	23.10 [15.60,	30.60]		5.34
Young-Xu	≥18	14+	Omicron	7.00 [3.50,	10.50]		5.52
Carazo	18-59	14+	BA.2	35.00 [27.50,	42.50]		5.34
Yoon	≥18	14+	Omicron	46.00 [28.00,	64.00]		4.42
Grewal	≥60	14+	Omicron	6.00 [-4.00,	16.00]	-	5.16
Heterogeneity: τ^2 = 218.84, I^2 = 93.91%, H^2 = 1	6.43			22.33 [8.62,	36.03]	•	
Test of $\theta_i = \theta_j$: Q(4) = 65.73, p = 0.00							
mRNA-1273 Within 3 months							
Tseng	≥18	14+	Omicron	13.90 [10.60,	17.20]		5.53
Tseng	≥18	14-90	Omicron	44.00 [35.60,	52.40]		5.28
Willet	≥18	14+	Omicron	23.70 [6.20,	41.20]		4.47
Hansen	≥60	15-44	Omicron	36.70 [-36.45,	109.85]		1.05
Heterogeneity: τ^2 = 344.93, I^2 = 93.09%, H^2 = 1 Test of $\theta_i = \theta_j$: Q(3) = 43.38, p = 0.00	4.46			27.81 [6.62,	49.00]	•	
CoronaVac Within 3 months							
Jara	3-5	14+	Omicron	37.80 [36.05.	39,551		5.56
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$				37.80 [36.05.	39.551	1	0.00
Test of $\theta_i = \theta_j$: Q(0) = -0.00, p = .					,	,	
BNT162b2 Within 3-6 months							
Hansen	≥60	105-164	Omicron	-76.50 [-94.40,	-58.60]	-	4.43
Fowlkes	12-15	14-149	Omicron	59.00 [30.50,	87.50]		3.37
Fowlkes	12-15	150+	Omicron	62.00 [3.50,	120.50]	-	1.49
Heterogeneity: τ^2 = 8371.56, I^2 = 97.25%, H^2 = Test of $\theta_i = \theta_j$: Q(2) = 72.82, p = 0.00	36.41			13.19 [-92.68,	119.05]		
BNT162b2/mRNA-1273 Within 3-6 months							
Lind	≥5	150+	BA.1	15.30 [10.50,	20.10]		5.48
Lind	≥5	14-149	BA.1	28.50 [20.40.	36.60]		5.30
Heterogeneity: $\tau^2 = 75.58$, $I^2 = 86.76\%$, $H^2 = 7.5$	55			21.48 [8.57,	34.39]	•	
Test of $\theta_i = \theta_j$: Q(1) = 7.55, p = 0.01						•	
mRNA-1273 Within 3-6 months							
Hansen	≥60	105-164	Omicron	-39.30 [-60.10,	-18.50]		4.14
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$				-39.30 [-60.10,	-18.50]	•	
Test of θ_i = $\theta_j;$ Q(0) = 0.00, p = .							
mRNA-1273 6+ months						<u>2</u> 29	
Tseng	≥18	270+	Omicron	5.90 [0.60,	11.20]		5.45
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$				5.90 [0.60,	11.20]	•	
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .							
Overall				20.40 [12.07,	28.72]	٠.	
Within 3months				28.09 [19.07,	37.11]	•	
Within 3-6 months				3.95 [-24.82,	32.72]	-	
6+ months				5.90 [0.60,	11.20]	. •	
Heterogeneity: τ^2 = 323.37, I^2 = 96.42%, H^2 = 2	7.90						
Test of $\theta_i = \theta_j$: Q(23) = 641.74, p = 0.00							
Test of group differences: $Q_b(8) = 184.59$, p = 0	.00						
					-1	00 -50 0 50 100	
Random-effects DerSimonian-Laird model							

Figure 2. VE estimates against SARS-CoV-2 infection of the Omicron variant after the primary course, by vaccine types and time intervals.

Study	Age	Time (days) Subvarian	Effect siz	e Cl		Weight (%)
AZD1222 Within 3 months							
UKHSA	≥18	14-28	Omicron	49.80 [41.40,	58.20]	T	2.63
Heterogeneity: r [*] = 0.00, l [*] = .%, H [*] = .				49.80 [41.40,	58.20]		
Test of $\theta_i = \theta_j$: $Q(0) = 0.00$, $p = .$							
BNT162b2 Within 3 months							
Altarawneh	≥18	14+	BA.1	-4.90 [-15.80,	6.00]		2.60
Altarawneh	≥18	14+	Omicron	-0.20 [-5.40,	5.00]		2.66
Altarawneh	≥18	14+	BA.2	-1.10 [-6.95,	4.75]		2.66
Buchan(a)	12-17	7-59	Omicron	51.00 [39.50,	62.50]		2.59
Chemaitelly	≥5	30-90	Omicron	51.70 [43.85,	59.55]	-	2.64
Chemaitelly	≥5	30-90	BA.1	46.60 [34.70,	58.50]		2.58
Chemaitelly	≥5	30-90	BA.2	51.70 [43.85,	59.55]		2.64
Powell	16-17	70+	Omicron	22.60 [14.90,	30.30]	· · · _	2.64
Powell	16-17	14-34	Omicron	71.30 [69.40,	73.20]		2.68
Powell	12-15	14+	Omicron	73.00 [67.05,	78.95]		2.65
UKHSA	≥18	14-28	Omicron	65.80 [64.40,	67.20]		2.68
Heterogeneity: $\tau^{-} = 603.89$, $\Gamma^{-} = 99.28\%$, $H^{-} = 1$	39.39			38.98 [24.27,	53.69]	•	
Test of $\theta_i = \theta_j$: Q(10) = 1393.86, p = 0.00							
BNT162b2/mRNA-1273 Within 3 months							
Buchan(b)	≥18	7-59	Omicron	36.00 [25.50.	46.501	-	2.60
Carazo	18-59	14+	BA.2	61.00 [52.50.	69.501		2.63
Grewal	≥60	14+	Omicron	23.00 [3.50.	42.501		2.43
Suarez-Castillo	≥18	0-30	Omicron	43.00 [41.00,	45.001		2.68
Heterogeneity: τ ² = 107.68, I ² = 86.80%, H ² = 7	.58			42.80 [31.35,	54.26]		
Test of $\theta_i = \theta_i$: Q(3) = 22.73, p = 0.00							
mRNA-1273 Within 3 months							
Altarawneh	≥18	14+	BA.1	-2.70 [-15.95,	10.55]	-	2.56
Altarawneh	≥18	14+	Omicron	2.20 [-4.35,	8.75]	-	2.65
Altarawneh	≥18	14+	BA.2	-7.30 [-14.95,	0.35]	-	2.64
Chemaitelly	≥5	30-90	Omicron	43.20 [19.65,	66.75]		2.33
Chemaitelly	≥5	30-90	BA.1	71.00 [38.50,	103.50]		2.08
Chemaitelly	≥5	30-90	BA.2	35.90 [2.35,	69.45]		2.05
UKHSA	≥18	14-28	Omicron	76.00 [72.50,	79.50]		2.67
Heterogeneity: τ^2 = 2417.84, I ² = 99.13%, H ² =	115.54			30.54 [-6.68,	67.77]		
Test of $\theta_i = \theta_j$: Q(6) = 693.23, p = 0.00							
AZD1222 Within 3-6 months		175			0.051	_	0.00
Kirsebom	40-64	175+	Omicron	8.00 [6.05,	9.95]	_	2.68
Kirsebom	≥65	175+	Omicron	19.50 [12.05,	26.95]		2.64
UKHSA	≥18	1/5+	Omicron	-1.00 [-2.35,	0.35]	•	2.68
Heterogeneity: 1" = 50.46, 1" = 97.38%, H" = 38	.13			8.01[-0.39,	16.41]	•	
Test of $\theta_i = \theta_j$. $Q(z) = 76.25$, $p = 0.00$							
BNT162b2 Within 3-6 months							
UKHSA	≥18	175+	Omicron	9.40 [7.75.	11.051		2.68
Heterogeneity: τ ² = 0.00, I ² = .%, H ² = .				9.40 [7.75,	11.05]	T	
Test of $\theta_i = \theta_i$: Q(0) = -0.00, p = .						1	
BNT162b2/mRNA-1273 Within 3-6 months							
Kim	≥18	14-149	Omicron	45.00 [19.00,	71.00]		2.26
Kim	≥15	150+	Omicron	11.00 [-17.00,	39.00]		2.21
Heterogeneity: $\tau^2 = 387.97$, $I^2 = 67.12\%$, $H^2 = 3$.04			28.41 [-4.90,	61.72]		
Test of $\theta_i = \theta_j$: Q(1) = 3.04, p = 0.08							
mRNA-1273 Within 3-6 months						· · · · ·	
	218	1/5+	Omicron	13.00 [3.50,	22.50]	—	2.62
Heterogeneity: f = 0.00, f = .%, H = .				13.00[3.50,	22.50]	•	
Test of $\theta_i = \theta_i$. $Q(0) = 0.00, p = 1$.							
BNT162b2 6+ months							
Buchan(a)	12-17	180+	Omicron	29.00 [18.50.	39.501		2.60
Chemaitelly	≥5	212+	BA.2	-12.10 [-24.40.	0.201		2.57
Chemaitelly	≥5	212+	Omicron	-9.00 [-18.10.	0.10]	-	2.62
Chemaitelly	≥5	212+	BA.1	-17.80 [-27.80.	-7.80]		2.61
Heterogeneity: r ² = 418.40, I ² = 93.73%, H ² = 1	5.95			-2.47 [-23.19,	18.26]		
Test of $\theta_i = \theta_i$: Q(3) = 47.86, p = 0.00					1000 AV 40		
BNT162b2/mRNA-1273 6+ months							
Buchan(b)	≥18	240+	Omicron	2.00 [-15.00,	19.00]		2.48
Suarez-Castillo	≥18	180+	Omicron	11.00 [9.50,	12.50]		2.68
Heterogeneity: $\tau^2 = 2.59$, $I^2 = 6.40\%$, $H^2 = 1.07$				10.65 [7.22,	14.07]	· •	
Test of $\theta_i = \theta_j$: Q(1) = 1.07, p = 0.30							
mRNA-1273 6+ months						_	
Chemaitelly	≥5	212+	Omicron	-13.70 [-21.05,	-6.35]	-	2.64
Chemaitelly	≥5	212+	BA.2	-20.40 [-36.10,	-4.70]		2.51
Chemaitelly	≥5	212+	BA.1	-10.20 [-22.40,	2.00]		2.58
Heterogeneity: $\tau^{z} = 0.00$, $I^{z} = 0.00\%$, $H^{z} = 1.00$				-13.83 [-19.67,	-7.98]		
Test of $\theta_i = \theta_j$: Q(2) = 1.01, p = 0.60							
0				00.404.45.11	00.007	A	
Overall With the Demonstration				23.40 [13.48,	33.33]		
Within 2.6 month -				37.09[26.94,	47.23]	A 🔻	
within 3-6 months				10.56 4.64,	10.52]		
Heterogeneity: $r^2 = 957.26$ $r^2 = 00.628/$ $r^2 = 0$	66.26			-4.32 [-15.37,	0.73]		
Therefore $H = 0.0(29) = 10119.04 = -0.00$	00.20						
$rest or o_i = o_j$. $ca(so) = 10110.01$, $p = 0.00$							
Test of group differences: $Q_b(10) = 201.42$, p =	0.00				-		
					-50	0 50	100
Random-effects DerSimonian-Laird model							

Figure 3. VE estimates against symptomatic Omicron infection after the primary course, by vaccine types and time intervals.



Figure 4. Scatterplot of VE against symptomatic Omicron infection plotted according to time from the primary vaccination.

3.2.4. VE against Omicron Infection after the First Booster Dose

A total of eight studies conducted in the USA (n = 4) [31,35,37,39], Canada (n = 2) [21,24] and UK (n = 2) [34,38] evaluated VE (17 different VE estimates) [34,38] against Omicron infection. The overall pooled VE estimate of the first booster dose against Omicron infection was 48.8% (95% CI: 42.0–55.6%, $I^2 = 97.3\%$) (Figure 6). The pooled VE estimates of the first booster dose after 7–14 days was 41.4% (95%CI: 32.4–503%, $I^2 = 79.8\%$) and increased to 51.2% (95%CI: 43.9–58.6%) within three months following three doses of any mRNA vaccines. Data from a single study during the same time period showed a slightly lower VE estimates of 47% (95%CI: 13–81%) following two dose adenovirus vector vaccines with one mRNA vaccine (Figure 6). There was insufficient follow-up period post three months to evaluate the waning of booster vaccination against Omicron infection.

3.2.5. VE against Symptomatic Infection after the First Booster Dose

A total of eight studies conducted across Canada (n = 4) [19–21,24], UK (n = 2) [25,33], France (n = 1) [27] and Qatar (n = 2) [18,22] evaluated VE of one booster dose (50 different VE estimates). The pooled VE of a booster dose against symptomatic infection was 55.9% (95%CI: 53.4–58.4%, $I^2 = 98.4$) (Figure 7). The VE varied by vaccine types and technology. The pooled VE estimates of three doses of mRNA vaccine after 7–14 days was 58.4% (95%CI: 54.8–62.0%, $I^2 = 83.7$ %). VE of the first booster dose remained stable up to three months following three doses of any mRNA vaccines (56.1%, 95%CI: 50.9–61.3%) or three doses of adenovirus vector vaccines (60.2%, 95%CI: 55.0–65.5%). Slightly lower VE estimates were observed for heterologous boosting using 2-dose adenovirus vector vaccines with one mRNA vaccine (51.7%, 95%CI: 50.9–61.3%). Between the periods three to six months, pooled VE estimates reduced to 32.8% (95%CI: 16.9–48.8%), waning less pronounced for three-dose, homologous mRNA vaccination (Figure 7).

itudy	Age	Time (days)	Subvarian	t w	ith 95%	CI		(%
NT162b2 Within 3 months							-	
20llie	≥15	14+	Omicron	69.00 [52.50,	85.50]		2.2
dams	218	14+	Omicron	46.00 [32.00,	60.00J		2.4
Itarawneh	>18	14+	BA 1	108.80	82 55	91.35]		2.3
ltarawneh	>18	14+	Omicron	73 50 [62.65	84 351		2.5
Suchan(a)	12-17	7-59	Omicron	76.00 [23.50	128.50]		0.8
artof(a)	>18	7-90	Omicron	68.00 [52.00.	84.001		2.2
artof(a)	≥18	7+	Omicron	62.00 [54.00.	70.001		2.6
artof(a)	≥18	7+	Omicron	47.00 [40.00.	54.001		2.7
artof(a)	≥18	7-90	Omicron	64.00 [53.00.	75.001	-	2.5
KHSA	≥18	14-28	Omicron	73.60 [49.80,	97.40]	_	1.8
eterogeneity: τ^2 = 183.98, I ² = 82.24%, H ² = est of $\theta_i = \theta_i$: Q(10) = 56.31, p = 0.00	5.63			67.20 [57.87,	76.54]	•	
NT162b2/mRNA-1273 Within 3 months								
uchan(b)	≥18	7-59	Omicron	55.00 [-43.00,	153.00] -		0.2
rewal	≥60	14+	Omicron	52.00 [36.00,	68.00]		2.2
auring	≥18	14+	Omicron	65.00 [53.00,	77.00]	-	2.5
uarez-Castillo	≥18	0-30	Omicron	29.00 [-28.50,	86.50]		0.7
uarez-Castillo	≥18	0-30	Omicron	46.00 [-2.00,	94.00]		0.9
uarez-Castillo	≥18	0-30	Omicron	28.00 [5.50,	50.50]		1.9
oung-Xu	≥18	14+	Omicron	44.00 [28.00,	60.00]	-	2.2
oung-Xu	≥18	14+	Omicron	75.00 [57.50,	92.50]		2.2
eterogeneity: τ [*] = 144.07, l [*] = 56.38%, H [*] = est of θ _i = θ _j : Q(7) = 16.05, p = 0.02	2.29			52.76 [40.56,	64.96]	•	
RNA-1273 Within 3 months								
lams	≥18	14+	Omicron	47.00 [32.00,	62.00]		2.3
larawneh	≥18	14+	BA.2	84.80 [60.95,	108.65]		1.8
tarawneh	≥18	14+	BA.1	88.80 [38.55,	139.05]	-	- 0.8
larawneh	≥18	14+	Omicron	66.30 [44.65,	87.95]		1.9
nemaitelly	≥5	30-90	Omicron	87.10[58.60,	115.60]		1.6
eng	≥18	14+	Omicron	84.50 [47.55,	121.45]		1.2
aterogeneity: $\tau^{c} = 243.28$, $l^{c} = 59.71\%$, $H^{c} =$ est of $\theta_{i} = \theta_{j}$: Q(5) = 12.41, p = 0.03	2.48			72.52 [55.70,	89.33]	-	
oronaVac Within 3 months								
ra	3-5	14+	Omicron	68.80 [33.75,	103.85]		1.3
ra	3-5	14+	Omicron	65.20 [52.60,	77.80]	-	2.4
eterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.0$ est of $\theta_i = \theta_i$: $Q(1) = 0.04$, $p = 0.85$	00			65.61 [53.75,	77.47]	•	
d26.COV2.S Within 3 months								
dams	≥18	14+	Omicron	41.00 [14.50,	67.50]	-	1.7
eterogeneity: τ ² = 0.00, I ² = .%, H ² = . est of θ _i = θ _j : Q(0) = 0.00, p = .				41.00 [14.50,	67.50]	-	
ZD1222 Within 3-6 months								
rsebom	≥65	175+	Omicron	61.00 [51.05,	70.95]	-	2.6
KHSA	≥18	140-168	Omicron	55.80 [37.70,	73.90]		2.1
KHSA	≥18	175+	Omicron	32.70 [20.75,	44.65]	-	2.5
eterogeneity: $\tau^2 = 237.49$, $I^2 = 84.77\%$, $H^2 =$ est of $\theta_i = \theta_i$: Q(2) = 13.13, p = 0.00	6.56			49.69 [30.60,	68.79]	•	
NT162b2 Within 3-6 months								
hemaitelly	≥5	30-182	Omicron	70.40 [50.90.	89.901		2.1
artof(b)	≥18	<182	BA.2	27.00 [-4.50.	58.501	_	1.4
artof(b)	≥18	<182	BA.2	56.00 [14.50,	97.50]	_	1.0
artof(b)	≥18	14-182	BA.1	42.00 [31.50,	52.50]	-	2.5
artof(b)	≥18	14-182	BA.1	54.00 [40.50,	67.50]	-	2.4
KHSA	≥18	175+	Omicron	34.90 [19.55,	50.25]		2.3
eterogeneity: τ ² = 100.00, I ² = 56.63%, H ² =	2.31			47.39 [36.15,	58.63]	•	
est of $\theta_i = \theta_j$: Q(5) = 11.53, p = 0.04								
					70 50	06 601	-	
NT162b2 6+ months	12 17	190+	Omisso-	00 nn '	19.00,	90.00]		2.6
NT162b2 6+ months ichan(a)	12-17	180+	Omicron	88.00 [60.05	0E 753		2.6
NT162b2 6+ months uchan(a) uemaitelly	12-17 ≥5	180+ 212+	Omicron Omicron	88.00 [69.25,	85.75]		
NT162b2 6+ months uchan(a) remaitelly rtof(a)	12-17 ≥5 ≥18	180+ 212+ 270+ 270+	Omicron Omicron Omicron	88.00 [77.50 [31.00 [69.25, 17.50,	85.75] 44.50]	-	2.4
VT162b2 6+ months cchan(a) nemaitelly rtof(a) rtof(a) control	12-17 ≥5 ≥18 ≥18	180+ 212+ 270+ 270+	Omicron Omicron Omicron	88.00 [77.50 [31.00 [41.00 [69.25, 17.50, 24.00,	85.75] 44.50] 58.00]	1	2.4
VT162b2 6+ months uchan(a) nematoliy vtrof(a) vtrof(a) vtrof(b) vtrof(b)	12-17 ≥5 ≥18 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+	Omicron Omicron Omicron BA.2 BA 1	88.00 [77.50 [31.00 [41.00 [56.00 [69.25, 17.50, 24.00, 33.50,	85.75] 44.50] 58.00] 78.50] 31.503		2.4 2.2 1.9
VT162b2 6+ months uchan(a) nemaitelly vrtof(a) vrtof(b) vrtof(b) vrtof(b)	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+	Omicron Omicron Omicron BA.2 BA.1 BA 1	88.00 [77.50 [31.00 [41.00 [56.00 [19.00 [69.25, 17.50, 24.00, 33.50, 6.50,	85.75] 44.50] 58.00] 78.50] 31.50] 46.50]		2.4 2.2 1.9 2.4
xT162b2 6+ months cchan(a) semaitally rtol(a) rtol(b) rtol(b) rtol(b) rtol(b) rtol(b) rtol(b)	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2	88.00 [77.50 [31.00 [41.00 [56.00 [19.00 [32.00 [69.25, 17.50, 24.00, 33.50, 6.50, 17.50,	85.75] 44.50] 58.00] 78.50] 31.50] 46.50]		2.4 2.2 1.9 2.4 2.3
IT162b2 6+ months chan(a) iemaitally ntol(a) ntol(a) ntol(b) ntol(b) ierogeneity: r ² = 909.21, l ² = 95.56%, H ² =	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2	88.00 [77.50 [31.00 [41.00 [56.00 [19.00 [32.00 [12.00 [45.00 [69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42,	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58]	* * * *	2.4 2.2 1.9 2.4 2.3 2.0
IT162b2 6+ months chan(a) emailelly rtof(a) rtof(b) rtof(b) rtof(b) rtof(b) tof(b) stof(b) stof(b, e ²) = 999.21, l ² = 95.56%, H ² = stof θ, = θ ₁ : Q(7) = 157.63, p = 0.00	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥2.52	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2	88.00 [77.50] 31.00] 41.00] 56.00] 19.00] 32.00] 12.00] 45.00]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42,	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58]	+++++++++++++++++++++++++++++++++++++++	2.4 2.2 1.9 2.4 2.3 2.0
XT162b2 6+ months tchan(a) termaitelly trof(a) trof(a) trof(b) trof(b) trof(b) trof(b) terogeneity: t ² = 909.21, l ² = 95.56%, H ² = st of θ ₁ = θ ₁ : Q(7) = 157.63, p = 0.00 XT162b2/mRNA-1273 6+ months chan(b)	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥22.52 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 240+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron	88.00 [77.50 [31.00 [41.00 [56.00 [19.00 [32.00 [12.00 [45.00 [86.00]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00.	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58]	•	2.4 2.2 1.9 2.4 2.3 2.0
VT162b2 6+ months uchan(a) hermatelly vtro((a) vtro((b) vtro((b) vtro((b) vtro((b) vtro((b) stro((b) vt	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥22.52 ≥18 ≥18	180+ 212+ 270+ 182+ 182+ 182+ 182+ 182+ 240+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron	88.00 [77.50 [31.00 [41.00 [56.00 [19.00 [32.00 [12.00 [45.00 [86.00 [50.00 [69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00, 43.50	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58]	•	2.4 2.2 1.9 2.4 2.3 2.0 - 0.7 2.7
AT162b2 6+ months tchan(a) hermatelly rtof(a) rtof(a) rtof(b) rtof(b) rtof(b) trof(b) setogeneily: $\gamma^2 = 909.21$, $l^2 = 95.56\%$, H^2 = st of $\theta_i = \theta_i$: $Q(7) = 157.63$, $p = 0.00$ AT162b2/mRNA-1273 6+ months tchan(b) arez-Castillo	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥22.52 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 182+ 182+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron Omicron	88.00 [77.50 [31.00 [41.00 [56.00 [19.00 [32.00 [45.00 [86.00 [50.00 [68.00]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00, 43.50, 57.50.	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58] 141.00] 56.50] 78.50]	•	2.4 2.2 1.9 2.4 2.3 2.0 - 0.7 2.7 2.5
xT162b2 6+ months tchan(a) ternatelity trot(a) trot(b) trot(c) trot(c) <	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥22.52 ≥18 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 182+ 180+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron Omicron	88.00 [77.50] 31.00 [41.00 [56.00] 19.00 [32.00 [45.00] 86.00 [50.00] 68.00 [49.00]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00, 43.50, 57.50, 34.50.	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58] 141.00] 56.50] 78.50] 63.50]	•	2.4 2.2 1.9 2.4 2.3 2.0 - 0.7 2.7 2.5 2.3
VT162b2 6+ months uchan(a) hermatelily vtrof(a) vtrof(b) vtrof(b) vtrof(b) vtrof(b) sterogeneiity: $r^2 = 909.21$, $l^2 = 95.56\%$, $H^2 = 1000$ VT162b2/mRNA-1273 6+ months uchan(b) vtrof(b)	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥2.52 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 180+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron Omicron	88.00 [77.50] 31.00 [41.00 [56.00 [19.00] 32.00 [12.00] 45.00 [50.00] 68.00 [68.00] 49.00 [57.04]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00, 43.50, 57.50, 34.50, 44.97,	85.75] 44.50] 58.00] 78.50] 31.50] 32.50] 66.58] 141.00] 56.50] 78.50] 63.50] 69.12]	•	2.4 2.2 1.9 2.4 2.3 2.0 - 0.7 2.7 2.5 2.3
NT162b2 6+ months uchan(a) shematelily intof(a) intof(a) intof(b) intof(b) intof(b) intof(b) intof(b) NT162b2/mRNA-1273 6+ months uchan(b) NT162b2/mRNA-1273 6+ months uchan(b) interz-Castillo interz-Castillo interz-Castillo isterz-Castillo isterz-Castillo istergeneiity: $r^2 = 90.08$, $l^2 = 70.01\%$, $H^2 = 1$; ust of $\theta_i = \theta_i$; Q(3) = 10.00, $p = 0.02$	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥22.52 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 180+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron Omicron	88.00 [77.50] 31.00 [41.00 [56.00] 12.00 [12.00] 45.00 [50.00] 68.00 [57.04]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00, 43.50, 57.50, 34.50, 44.97,	85.75] 44.50] 58.00] 31.50] 46.50] 32.50] 66.58] 141.00] 56.50] 78.50] 63.50] 69.12]	•	2.4 2.2 1.9 2.4 2.3 2.0 0.7 2.5 2.3
NT162b2 6+ months uchan(a) hemaitelly artof(a) artof(b) artof(b) artof(b) blerogeneity: $\tau^2 = 909.21$, $l^2 = 95.56\%$, $H^2 =$ est of $\theta_1 = \theta_1$. Q(7) = 157.63, $p = 0.00$ NT162b2/mRNA-1273 6+ months uchan(b) uarez-Castillo uarez-Castillo areze-Castillo areze-Castillo serogeneity: $\tau^2 = 90.08$, $l^2 = 70.01\%$, $H^2 =$; est of $\theta_1 = \theta_1$: Q(3) = 10.00, $p = 0.02$ verall	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥2.52 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥3.33	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 182+ 180+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron	88.00 [77.50] 31.00 [41.00 [56.00] 12.00 [12.00 [45.00] 86.00 [50.00] 68.00 [57.04] 56.93]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00, 43.50, 57.50, 34.50, 44.97, 51.40,	85.75] 44.50] 58.00] 31.50] 46.50] 32.50] 66.58] 141.00] 56.50] 78.50] 63.50] 63.50] 69.12]	•	2.4 2.2 1.9 2.4 2.3 2.0 - 0.7 2.7 2.5 2.3
NT162b2 6+ months Lichan(a) hemaitelly virtof(a) virtof(b) virtof(b) virtof(b) virtof(b) virtof(b) terrogeneity: $r^2 = 909.21$, $l^2 = 95.56\%$, $H^2 = 100$ virtof(b) virtof	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥22.52 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18 ≥18	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 240+ 180+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron Omicron	88.00 [77.50 [31.00 [41.00 [56.00 [12.00 [45.00 [45.00 [68.00 [68.00 [57.04 [56.93 [63.56]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00, 43.50, 57.50, 34.50, 44.97, 51.40, 57.45,	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58] 141.00] 56.50] 78.50] 63.50] 63.50] 63.50] 69.12]		2.4 2.2 1.9 2.4 2.3 2.0 0.7 2.7 2.5 2.3
NT162b2 6+ months uchan(a) premately intof(a) intof(a) intof(b) intof(b) intof(b) intof(b) intof(b) intof(b) NT162b2/mRNA-1273 6+ months uchan(b) NT162b2/mRNA-1273 6+ months uchan(b) intarez-Castillo areze-Castillo areze-Castillo isterogeneiity: $r^2 = 90.08$, $l^2 = 70.01\%$, $H^2 = r$ ist of $\theta_i = \theta_i$; Q(3) = 10.00, $p = 0.02$ verall tihtin 3-6 months tihtin 3-6 months	12-17 ≥5 ≥18 ≥18 ≥18 ≥18 ≥18 ≥22.52 ≥18 ≥18 ≥18 ≥18 ≥18 3.33	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 182+ 180+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron Omicron	88.00 [77.50] 31.00 [41.00 [19.00 [32.00 [12.00] 45.00 [68.00 [50.00] 49.00 [57.04] 56.93 [63.56] 48.31]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, -8.50, 23.42, 31.00, 43.50, 57.50, 34.50, 44.97, 51.40, 57.45, 38.99,	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58] 141.00] 56.50] 78.50] 63.50] 69.12] 62.45] 69.67] 57.63]		2.4 2.2 1.9 2.4 2.3 2.0 - 0.7 2.7 2.5 2.3
NT162b2 6+ months uchan(a) hermatelly intro(a) intro(a) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(c) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) intro(b) int	12-17 25 218 218 218 218 218 218 218 218	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 180+ 180+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron Omicron	88.00 [77.50] 31.00 [41.00] 56.00 [19.00 [32.00] 12.00 [45.00 [68.00] 68.00 [68.00] 57.04 [56.93] 63.56 [49.07]	69.25, 17.50, 24.00, 33.50, 6.50, 17.50, 23.42, 31.00, 43.50, 57.50, 34.50, 44.97, 51.40, 57.45, 38.99, 35.74,	85.75] 44.50] 58.00] 78.50] 31.50] 46.50] 32.50] 66.58] 141.00] 56.50] 78.50] 63.50] 63.50] 63.50] 63.51] 62.45] 69.67] 57.63] 63.65]		2.4 2.2 1.9 2.4 2.3 2.0 0.7 2.7 2.5 2.3
IT 162b2 6+ months chan(a) iemaitally trot(a) trot(a) trot(a) trot(b) trot(b) trot(b) terogeneity: $r^2 = 909.21$, $l^2 = 95.56\%$, $H^2 = 42$ at of $\theta_1 = \theta_1 \cdot O(7) = 157.63$, $p = 0.00$ IT 162b2/mRNA-1273 6+ months chan(b) arez-Castillo arez-Castillo arez-Castillo arez-Castillo trot(b) = 0.08, $l^2 = 70.01\%$, $H^2 = 12$ at of $\theta_1 = \theta_1 \cdot O(3) = 10.00$, $p = 0.02$ verall thin 3-months thin 3-f months months terogeneity: $r^2 = 279.67$, $l^2 = 84.37\%$, H^2	12-17 25 218 218 218 218 218 218 218 218	180+ 212+ 270+ 270+ 182+ 182+ 182+ 182+ 182+ 180+ 180+ 180+ 180+	Omicron Omicron Omicron BA.2 BA.1 BA.1 BA.2 Omicron Omicron Omicron	88.00 [77.50 [31.00] 41.00 [9.00 [9.00] 32.00 [12.00 [45.00] 45.00 [86.00 [68.00 [57.04 [9.00] 57.04 [49.00] 57.04 [49.00] 49.00 [48.31 [49.70 [69.25, 17.50, 24.00, 33.50, 6.50, 7.50, -8.50, 23.42, 31.00, 43.50, 57.50, 34.50, 44.97, 51.40, 57.45, 38.99, 35.74,	85.75] 44.50] 58.00] 78.50] 46.50] 32.50] 66.58] 141.00] 56.50] 78.50] 63.50] 63.50] 63.63] 69.12] 62.45] 63.65]		2.4 2.2 1.9 2.4 2.3 2.0 0

Figure 5. VE estimates against severe COVID-19 due to Omicron infection after the primary course by vaccine types and time intervals.

Study	A	Subvariant Time	(dave)	Effect siz	ze		Weight
3-doso mPNA Within 7-14 days	Age	Subvariant Time	(uays)	With 93%	CI		(70)
Growal	>60	Omicron 7+		36 00 [28 00	44 001		6 30
Growal	200	Omicron 7+		44.00 [28.00,	44.00]		6.30
Grewel	200	Omicron 7+	F	22.00 [25.00,	49.50]		6.00
Veen	≥00 >10	Omicron 7+		52.00 [25.00,	39.00J		6.43 E 16
Heterogeneity $z^2 = 62.25$ $l^2 = 70.78\%$ $H^2 = 4.05$	210	Officion 7+	r i	44.25 [22.44	75.00J		5.10
Heterogeneity: $T = 62.35$, $T = 79.76\%$, $\Pi = 4.95$				41.35 [32.44,	50.25J		
Test of $\theta_i = \theta_j$. Q(3) = 14.84, p = 0.00							
3-dose mRNA Within 3 months							
Carazo	18-59	BA.2 14	++	46.00 [40.00,	52.00]		6.55
Grewal	≥60	Omicron 14	1-84	39.00 [33.00,	45.00]		6.55
Grewal	≥60	Omicron 84	1+	37.00 [31.00,	43.00]	-	6.55
Montez-Rath	≥18	Omicron 21	+	53.00 [39.50,	66.50]		5.42
Spensley	≥18	Omicron 14	++	66.00 [43.50,	88.50]		3.93
Tseng	≥18	Omicron 14	++	29.40 [4.55,	54.25]		3.59
Tseng	≥18	Omicron 14	++	70.00 [68.05,	71.95]		6.86
Tseng	≥18	Omicron 60)+	47.40 [40.90,	53.90]	-	6.49
Tseng	≥18	Omicron 14	1-60	71.60 [69.75,	73.45]		6.86
Willet	≥18	Omicron 14	1+	43.22 [38.37,	48.07]	-	6.66
Willet	≥18	Omicron 14	1+	46.38 [41.53,	51.23]	-	6.66
Young-Xu	≥18	Omicron 14	1+	59.00 [57.00,	61.00]		6.86
Heterogeneity: τ ² = 146.27, I ² = 97.56%, H ² = 41.05				51.19 [43.85,	58.54]	•	
Test of $\theta_i = \theta_j$: Q(11) = 451.59, p = 0.00							
2-dose adenovirus vector + one mRnA Within 3 months							
Spensley	≥18	Omicron 14	1+	47.00 [13.00.	81.00]		- 2.53
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$				47.00 [13.00,	81.00]		-
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .							
Overall				48 83 [42 03	55 641		
Within 7-14 days				40.00 [42.00,	50.251		
Within 3 months				51 07 [43 84	58 301		
Heterogeneity: $r^2 = 17455 ^2 = 9734\% H^2 = 3755$				01.07 [40.04,	00.001	-	
Test of $\theta_{-} = \theta_{-} O(16) = 600.80 \text{ n} = 0.00$							
1001010, = 0, Q(10) = 000.00, p = 0.00							
Test of group differences: $Q_b(2) = 2.80$, p = 0.25					Ţ		
					0	60	100

Random-effects DerSimonian-Laird model

Figure 6. VE estimates against SARS-CoV-2 infection of the Omicron variant after one booster dose by vaccine types and time intervals.

3.2.6. VE against Severe Omicron Infection after the First Booster Dose

A total of 11 studies (39 different VE estimates) conducted in the USA (n = 5) [17,26,28–30], Canada (n = 3) [20,21,24], Qatar (n = 2) [18,22] and France (n = 1) [27] evaluated VE against severe Omicron infection. The pooled VE estimate of the first booster dose against severe Omicron disease was 86.5% (95%CI: 84.4–88.6%, $I^2 = 90.0\%$). The pooled VE estimates at 7–14 days was 88.1% (95%CI: 85.0–91.2%), 85.1% (95%CI: 80.2–90.1%) within 3 months and 88.0% (95%CI: 80.7–91.2%) within three to six months (three doses of any mRNA vaccines representing most of the pooled VE estimates) (Figure 8).

3.2.7. VE of a Second Booster or Fourth Dose

One study evaluated the VE of a fourth dose (second booster dose) of mRNA-1273 in older residents of long term care facilities in Ontario, Canada [24]. The pooled VE estimate of a fourth dose of mRNA-1273 followed by any combination of three mRNA vaccines at "≈7 days" against Omicron infection was 50.3% (95%CI: 47.1–53.6%), 69.7% (95%CI: 65.3–74.2%) against symptomatic Omicron infection, and 86% (95%CI: 81–90%) against severe outcomes (Figures S3–S5). There was no VE data for other time periods.

Study	Age	Subvariant	Time (days)	E	ffect size th 95% C))		Weight (%)
3-dose mRNA Within 7-14 days								
Altarawneh	≥18	Omicron	7+	54.00 [50.55,	57.45]		2.56
Altarawneh	≥18	BA.2	7+	52.20 [48.30,	56.10]		2.53
Altarawneh	≥18	BA.2	7+	52.90 [43.80,	62.00]		1.99
Altarawneh	≥18	BA.1	7+	56.50 [40.85,	72.15]	-	1.32
Altarawneh	≥18	Omicron	7+	61.30 [54.00,	68.60]		2.19
Altarawneh	≥18	BA.1	7+	59.60 [53.40,	65.80]		2.31
Buchan(a)	12-17	Omicron	7	56.00 [38.00,	74.00]		1.13
Buchan(a)	12-17	Omicron	7+	62.00 [50.50,	73.50]		1.72
Buchan(b)	>18	Omicron	7+	65.00 [56.50	73 501		2.43
Grewal	>60	Omicron	7+	57.00 [42 50	71 501	-	1.42
Grewal	>60	Omicron	7+	61.00 [51.50	70.501		1.94
Grewal	≥60	Omicron	7+	53.00 [41.00,	65.00]		1.67
Suarez-Castillo	≥18	Omicron	8-14	64.00 [63.50,	64.50]		2.69
Heterogeneity: r ² = 30.39, I ² = 83.70%, H ² = 6.14				58.42 [54.75,	62.09]		
Test of $\theta_i = \theta_j$: Q(13) = 79.77, p = 0.00								
3-dose mRNA Within 3 months								
UKHSA/Andrews	≥18	Omicron	29-63	65.30 [63.15,	67.45]		2.64
UKHSA/Andrews	≥18	Omicron	14-28	68.00 [64.00,	72.00]		2.52
UKHSA/Andrews	≥18	Omicron	14-28	74.70 [73.70,	75.70]		2.68
UKHSA/Andrews	≥18	Omicron	14-28	68.70 [67.90,	69.50]		2.68
	218	Omicron	14 28	50.10 [49.00,	51.20]		2.67
Carazo	<10 19.50	BA 2	14-28	70.00 [63.50,	76.50]		2.56
Chemaitelly	>5	BA 2	14-30	43 70 1	36.95	50.451		2.20
Chemaitelly	≥5	BA.2	30+	41.90 [25.60	58,201	-	1.26
Chemaitelly	≥5	Omicron	43+	90.101	82.90	97,301		2.20
Chemaitelly	≥5	BA.2	30+	40.20 [34.45	45.951		2.36
Chemaitelly	≥5	BA.1	14-30	51.50 [35.05,	67.95]	-	1.25
Chemaitelly	≥5	BA.2	14-30	39.40 [26.20,	52.60]	-	1.54
Chemaitelly	≥5	BA.1	30+	40.50 [31.50,	49.50]		2.00
Chemaitelly	≥5	BA.1	30+	45.30 [22.45,	68.15]		0.84
Chemaitelly	≥5	BA.1	14-30	59.90 [52.00,	67.80]		2.12
Chemaitelly	≥5	Omicron	30+	47.50 [35.50,	59.50]	-	1.67
Chemaitelly	≥5	Omicron	30+	39.40 [34.60,	44.20]		2.45
Chemaitelly	≥5	Omicron	14-42	81.80 [8.15,	155.45]		0.11
Chemaitelly	≥5	Omicron	14-30	43.60 [34.00,	53.20]		1.93
Chemaitelly	≥5	Omicron	14-30	49.50 [44.60,	54.40]		2.44
Grewal	≥60	Omicron	14-84	62.00 [52.00,	72.00]		1.89
Grewal	≥60	Omicron	84+	55.00 [45.50,	64.50]		1.94
Heterogeneity: $T = 133.84$, $F = 98.58\%$, $H = 70.37$ Test of $\theta_i = \theta_j$: Q(22) = 1548.04, p = 0.00				56.11[50.94,	61.28]		
3-dose adenovirus vector-Within 3 months								
Kirsehom	>65	Omicron	14-34	51 60 [26.80	76 401		0.74
Kirsebom	40-64	Omicron	14-34	51.70 [40.25	63.151		1.73
Heterogeneity: $r^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$				51.68 [41.29.	62.081		
Test of $\theta_i=\theta_j;$ Q(1) = 0.00, p = 0.99				-				
2-dose adenovirus vector + one mRnA Within 3 months								
UKHSA/Andrews	≥18	Omicron	14-28	70.30 [69.55,	71.05]		2.68
UKHSA/Andrews	≥18	Omicron	29-63	61.60 [60.05,	63.15]		2.66
UKHSA/Andrews	≥18	Omicron	14-28	62.70 [62.00,	63.40]		2.68
UKHSA/Andrews	≥18	Omicron	70+	44.10 [42.25,	45.95]		2.65
Kirsebom	40-64	Omicron	14-34	63.80 [63.05,	64.55]		2.68
Kirsebom	≥65	Omicron	14-34	58.10[52.00,	64.20]	-	2.32
Heterogeneity: τ [*] = 41.34, l [*] = 99.33%, H [*] = 148.19 Test of θ _i = θ _i : Q(5) = 740.96, p = 0.00				60.21 [54.96,	65.46]	1	
3-dose mRNA Within 3-6 months								
Suarez-Castillo	≥18	Omicron	90+	50.00 ſ	48.50	51.501		2.66
Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$				50.00 [48.50	51.501	T	2.00
Test of $\theta_i=\theta_j;Q(0)=0.00,p=$.								
3-dose adenovirus vector Within 3-6 months								
Kirsebom	40-64	Omicron	105+	37.20 [-21.15,	95.55]		0.17
Kirsebom	≥65	Omicron	70-104	-27.20 [-	108.05,	53.65]		0.09
Heterogeneity: r ² = 779.71, I ² = 37.60%, H ² = 1.60				11.33 [-50.55,	73.21]		
Test of $\theta_i = \theta_j$: Q(1) = 1.60, p = 0.21								
2-dose adenovirus vector + one mRnA Within 3-6 months								
Kirsebom	≥65	Omicron	105+	23.10 [15.40,	30.80]		2.15
Kirsebom	40-64	Omicron	105+	30.60 [26.85,	34.35]		2.54
Heterogeneity: $\tau^{-} = 18.58$, $1^{+} = 66.05\%$, $H^{2} = 2.95$				27.63 [20.45,	34.82]		
rest or $\theta_1 = \theta_1$; Q(1) = 2.95, p = 0.09								
Overall				55 80 1	53 37	58 401	1	
Within 7-14 days				58 42 1	54 75	62.091	1	
Within 3 months				57.26 [54.01	60.501	1	
Within 3-6 months				32.83 [16.87	48.791	.	
Heterogeneity: r ² = 61.24, l ² = 98.44%, H ² = 64.04							•	
Test of $\theta_i = \theta_j$: Q(49) = 3138.14, p = 0.00								
Test of group differences; $Q_{h}(6) = 75.02$, $p = 0.00$								
- · · · · · · · · · · · · · · · · · · ·						-100	0 100	200

Random-effects DerSimonian-Laird model

Figure 7. VE estimates against symptomatic Omicron infection after one booster dose by vaccine types and time intervals.

Study	Age Subvariant	Time (days)	Effect size) with 95% CI	Weigh (%)
3-dose mRNA Within 7-14 days				
Grewal	≥60 Omicron	7+	77.00 [69.00, 85.00]	2.50
Adams	≥18 Omicron	7+	80.00 [74.00. 86.00]	2.97
Altarawneh	≥18 BA.2	7+	98.20 [94.35, 102.05]	3.45
Altarawneh	>18 BA 1	7+	97 50 [83 45 111 55]	143
Altarawneh	>18 Omicron	7+	92 50 [86 55 98 45]	2 98
Growol	≥ f0 Omicron	7.	92.00 [00.00, 90.40]	2.30
	200 Onicion	0.44		1.90
Suarez-Castillo	≥18 Omicron	8-14	95.00 [89.50, 100.50]	3.08
Suarez-Castillo	≥18 Omicron	8-14	96.00 [92.50, 99.50]	3.52
Adams	≥18 Omicron	7+	70.00 [44.00, 96.00]	
Suarez-Castillo	≥18 Omicron	8-14	90.00 [87.50, 92.50]	3.69
Buchan(b)	≥18 Omicron	7+	95.00 [89.50, 100.50]	3.08
Grewal	≥60 Omicron	7+	81.00 [75.00, 87.00]	2.97
Buchan(b)	≥18 Omicron	7+	93.00 [81.00, 105.00]	
Adams	≥18 Omicron	7+	77.00 [69.00, 85.00]	2.50
Lauring	≥18 Omicron	7+	86.00 [79.00, 93.00]	2.73
Altarawneh	≥18 Omicron	7+	82.70 [-6.55, 171.95]	0.06
Heterogeneity: $r^2 = 38.36$, $l^2 = 81.65\%$, $H^2 = 5.45$			88.41 [84.69 92.12]	1
Test of $\theta_i = \theta_j$: Q(15) = 81.75, p = 0.00				
3-dose adenovirus vector Within 7-14 days				
Kirsebom	≥65 Omicron	7+	82.30 [68.75, 95.85]	1.50
Heterogeneity: $\tau^{z} = 0.00$, $I^{z} = .\%$, $H^{z} = .$			82.30 [68.75, 95.85]	•
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .				
2-dose adenovirus vector + one mRnA Within 7-14 days				
Kirsebom	≥65 Omicron	7+	90.90 [88.90, 92.90]	3.76
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$			90.90 [88.90, 92.90]	
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .				
2-dose viral vector-Within 7-14 days				
Adams	≥18 Omicron	7+	30.00 [-49.50, 109.50]	0.07
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$			30.00 [-49.50, 109.50] 🔫	
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .				
1-dose viral vector + one mRNA Within 7-14 days				
Adams	≥18 Omicron	7+	64.00 [41.50, 86.50]	0.72
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$			64.00 [41.50, 86.50]	•
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .				
3-dose mRNA Within 3 months				
Tartof(a)	≥18 Omicron	14-90	77.00 [72.50, 81.50]	3.31
Tartof(a)	≥18 Omicron	14+	82.00 [77.00, 87.00]	3.20
Tartof(b)	≥18 BA.1	7-90	80.00 [75.00, 85.00]	3.20
Tartof(a)	>18 Omicron	14+	75.00 [70.50, 79.50]	3.31
Tartof(a)	>18 Omicron	14-90	85.00 [80.50 89.50]	3 3 1
Crewel		04	77.00 [70.50, 83.50]	3.51
Grewal	260 Omicron	04+	77.00 [70.50, 83.50]	2.83
Chemaitelly	≥5 Omicron	14-42	90.90 [82.15, 99.65]	2.34
Thompson	≥18 Omicron	14+	94.00 [93.00, 95.00]	3.86
Thompson	≥18 Omicron	14+	90.00 [83.00, 97.00]	2.73
Young-Xu	≥18 Omicron	14+	87.00 [81.50, 92.50]	3.08
Young-Xu	≥18 Omicron	14+	94.00 [87.50, 100.50]	2.85
Tseng	≥18 Omicron	14+	99.20 [87.35, 111.05]	- 1.75
Grewal	≥60 Omicron	14-84	80.00 [73.00, 87.00]	2.73
Heterogeneity: T ² = 73.71, I ² = 93.69%, H ² = 15.85			85.14 [80.17, 90.12]	
Test of $\theta_i = \theta_j$: Q(12) = 190.19, p = 0.00				
3-dose mRNA Within 3-6 months				
Tartof(a)	≥18 Omicron	90+	53.00 [38.00, 68.00]	
Tartof(a)	≥18 Omicron	90+	55.00 [33.50, 76.50]	
Tartof(b)	≥18 BA.2	90+	76.00 [69.50, 82.50]	2.85
Suarez-Castillo	≥18 Omicron	90+	93.00 [90.50, 95.50]	3.69
Suarez-Castillo	≥18 Omicron	90+	93.00 [92.00, 94.00]	3.86
Suarez-Castillo	≥18 Omicron	90+	97.00 [95.00, 99.00]	3.76
Heterogeneity: $\tau^2 = 28.78$. $I^2 = 93.80\%$ $H^2 = 16.13$			86.02 80.86. 91 181	۰
Test of $\theta_i = \theta_j$: Q(5) = 80.66, p = 0.00				
Overall			86.49 [84.38, 88.61]	ł
Within 7-14 days			88.08 [84.99, 91.17]	•
Within 3 months			85.14 [80.17, 90.12]	
Within 3-6 months			88.02 [80.66, 91.18]	
Heterogeneity: r ² = 29.95, l ² = 90.04%. H ² = 10.04				
Test of $\theta_i = \theta_i$; Q(38) = 381.62, p = 0.00				
rest of group alterences: $Q_b(6) = 14.91$, p = 0.02			-50	0 50 100 150
Random-effects DerSimonian-Laird model				

Figure 8. VE estimates against severe COVID-19 due to Omicron infection after one booster dose by vaccine types and time intervals.

3.3. Subgroup Analyses

Subgroup VE analyses were performed by age, and sub-lineage of Omicron. For some subgroup analyses, there were not enough data points to estimate VE or duration of protection at different time points.

3.4. VE by Age Groups

3.4.1. Pediatric population

The pooled VE estimate for primary vaccination series (CoronaVac or BNT162b2) against Omicron infection in children under 12 years of age was 37.8% (95%CI: 36.0–39.5%) (Figure S6).

3.4.2. Adolescents

The pooled VE against Omicron infection following a two-dose BNT162b2 was 59.3% (95%CI: 40.7–77.9%) (Figure S6) and 49.7% (95%CI: 29.9–69.4%) against symptomatic infection in adolescents aged 12–18 years of age (Figure S7).

3.4.3. Middle Aged Adults

One study reported VE (8%; 95%CI: 6.0–9.9%) of symptomatic infection in middle aged adults 40–64 (Figure S7) [25]. The pooled VE against symptomatic Omicron infection for a primary series plus one booster of mRNA vaccine or AstraZeneca vaccine dose was 47.4% (95%CI: 23.3–71.5%) (Figure S8).

3.4.4. Older Adults

We observed a trend towards lower VE in the older age group (\geq 60 years of age). The pooled VE against any documented Omicron infection in older individual's \geq age 60 year was -6.9% (95%CI: -51.9-38.1%) following any two primary mRNA doses (BNT162b2 or mRNA-1273) (Figure S9). The pooled VE estimated for the first three months was 30.3 (95%CI: -10.0-70.7%) and substantially reduced to -58.2% (95%CI: -94.7-21.8%) within three to six months (Figure S10). There were not enough time data points to estimate VE longer than six months. Primary vaccination plus one booster dose of either the BNT162b2 or mRNA-1273 vaccines restored the protection to 57.9% (95%CI: 53.4-62.4%) within 3 months, and declined to 14.7% (95%CI: -22.0-51.5%) at six months (Figure S11). The pooled VE against severe infection following primary vaccine series was 58.5% (95%CI: 50.0-66.9%) (Figure S12) and increased to 81.6% (95%CI: 75.5-87.6%) following administration of one booster dose of mRNA or Vector vaccine (Figure S12). VE of the first booster dose against severe infection was 83.0% (95%CI: 76.0-90.0%) after \geq 7 days and remained stable at 3 months (78.4%, 95%CI: 73.6-83.2%) (Figure S13). VE of the second booster dose against severe COVID-19 illness was estimated to be 86.8% as discussed above (Figure S5).

3.5. VE by Omicron Sub Linages

Only two studies reported VE for Omicron sub linages BA.1 [26] and BA.2 [21], whilst four studies [18,21,22,29] evaluated 26 different VE estimates against symptomatic Omicron infection by sub linages BA.1 and BA.2. Therefore, stratified meta-analysis on VE was only conducted for the latter. The primary series provided similar pooled VE against symptomatic Omicron BA.1 infection (11.3%, 95%CI: –11.3–33.8%) and BA.2 infection (15.1%, 95%CI: –10.2–40.3%) (Figure S14). VE of the first booster dose against symptomatic Omicron BA.1 was slightly higher for BA.1 (53.2%, 95%CI: 45.6–60.8%) compared to BA.2 (49.3%, 95%CI: 50.0–57.6%) (Figure S15). Pooled VE against severe BA.1 Omicron infection for the primary series plus one booster dose of any mRNA vaccine was 87.4% (95%CI: 70.5–104.4%), and for a primary series alone was 52.7% (95%CI: 29.4–76.0%). Similarly, pooled VE against severe BA.2 infection following primary series was 52.5% (95%CI: 27.5–77.6%) and increased to 87.3% following one booster of mRNA vaccination (Figures S16 and S17).

Additionally, we performed sensitivity analyses by study designs (cohort or casecontrol) and statistical methods employed to estimate the VE (Logit, Poisson, and Cox regression models). These subgroup analyses did not reveal any meaningful differences to the overall VE findings against all outcomes (noting small numbers in some subgroups) (Data not shown).

4. Discussion

Our meta-analysis of 28 studies, which included nearly 11 million individuals, provides evidence on VE and duration of protection of COVID-19 vaccines against SARS-CoV-2 Omicron infection and severe COVID-19. Our data suggest that primary vaccination series are not sufficiently protective against the Omicron infection and protection wanes substantially over time from 28% at three months to 4% at six months. Similar trends were observed for symptomatic Omicron infection following full vaccination, broadly consistent with recent review findings [14,40,41]. The waning of primary COVID-19 vaccination course was less pronounced against severe Omicron disease, decreasing from 64% at three months to 49% after six months, consistent with recent findings [14,40,41].

Our meta-analysis suggests that first booster dose restores and provides additional protection for all outcomes. VE of the first booster dose against any (51%) or symptomatic (57%) Omicron infection remained moderate for at least 3 months. Although there was limited data for longer follow-up, VE of the first booster dose against symptomatic Omicron infection waned to 33% at six months, falling below the WHO's minimal criteria of 50% when considering the outcomes of infection and symptomatic disease. This suggests the waning effect is also present for booster vaccination, consistent with recent studies conducted during the Omicron-dominant period [42–44]. However, our review suggests that protection against severe Omicron cases remained robust up to 86% after a single dose of booster for at least up to six months, corroborating recent findings [14,40,41].

Vaccine waning following booster vaccination was lower among the younger age group compared to the older adults aged ≥ 60 years. VE of the second booster dose against symptomatic Omicron infection declined more rapidly in older adults aged ≥ 60 years from 58% at three months to 14% at six months [24]. However, high level protection against severe disease still remained up to 78% for at least six months after the second booster dose in older adults, who are more vulnerable to severe COVID-19 outcomes. As of 28 November 2022, 68.5% of the world population have not received booster doses [45]. Future research should continue to evaluate the VE of booster vaccination with longer follow-ups to determine the duration of protection against the Omicron variant.

This meta-analysis had several limitations. The included studies were highly heterogeneous in terms of study populations, statistical approaches employed, definitions of symptomatic or severe COVID-19 used, analysed time points after vaccination, and vaccination schedules and regimes. All these factors may contribute to the discrepancy in our VE estimates and limit the generalizability of our results. Although the included studies made some sort of adjustments to their final VE estimates, not all accounted for important confounders, such as previous SARS-CoV-2 infection, underlying comorbidities, socio-economic parameters and COVID mitigation strategies.

5. Conclusions

This meta-analysis from a wide variety of study types, settings and populations demonstrates that primary COVID-19 vaccination courses were limited in preventing infections and severe disease caused by the SARS CoV-2 Omicron variant. Our review highlights the importance of booster doses for protection against Omicron infection and, more importantly, in providing high levels of protection against severe Omicron disease, particularly among the elderly population. Further research on the real-world performance of the existing vaccines including the new Omicron-specific vaccines is needed.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/vaccines11020224/s1. Supplementary Material S1: Search Terms. Supplementary Material S2: Summary of quality assessments of the included studies using JBI appraisal checklist. Supplementary Material S3. List of covariates used in final analyses of vaccine effectiveness (VE) estimates from the included primary studies. Figure S1: Scatterplot of VE against SARS-CoV-2 infection of the Omicron variant plotted according to time from the primary vaccination course. Figure S2: Scatterplot of VE against severe COVID-19 due to Omicron infection plotted according to time from the primary vaccination course. Figure S3: VE estimates against SARS-CoV-2 infection of the Omicron variant after two booster dose in older adults aged ≥ 60 years. Figure S4: VE estimates against symptomatic Omicron infection after two booster dose in older adults aged \geq 60 years. Figure S5: VE estimates against severe COVID-19 due to Omicron infection after two booster dose in older adults aged \geq 60 years. Figure S6: VE estimates against SARS-CoV-2 infection of the Omicron variant after the primary vaccination course, by age group. Figure S7: VE estimates against symptomatic Omicron infection after the primary vaccination course, by age group. Figure S8: VE estimates against symptomatic Omicron infection after one booster dose, by age group. Figure S9: VE estimates against severe COVID-19 due to Omicron infection after the primary vaccination course, by age group. Figure S10: VE estimates against SARS-CoV-2 infection of the Omicron variant after the primary vaccination course, by age group. Figure S11: VE estimates against SARS-CoV-2 infection of the Omicron variant after the primary vaccination course in older adults aged ≥ 60 years, by time intervals. Figure S12: VE estimates against severe COVID-19 due to Omicron infection after the primary vaccination course, by age group. Figure S13: VE estimates severe COVID-19 due to Omicron infection after one booster dose in older adults aged ≥ 60 years, by time intervals. Figure S14: VE estimates against symptomatic Omicron infection after the primary vaccination course, by Omicron sub-variants. Figure S15: VE estimates against symptomatic Omicron infection after one booster dose, by Omicron sub-variants. Figure S16: VE estimates against severe Omicron infection after the primary vaccination course, by Omicron sub-variants. Figure S17: VE estimates against severe Omicron infection after one booster dose, by Omicron sub-variants.

Author Contributions: Conceptualization, H.M., B.W., M.M., P.H.A. and H.S.M.; literature search and review, H.M., D.D.P.-T. and Z.Y.M.Y.; data extraction, H.M., D.D.P.-T. and Z.Y.M.Y.; data analysis, H.M. and B.W.; writing—original draft preparation, H.M.; writing—review and editing, H.M., D.D.P.-T., Z.Y.M.Y., B.W., M.M., P.H.A. and H.S.M.; All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data generated from the study have been included in the manuscript. Data were obtained from the primary studies included in the review.

Conflicts of Interest: H.S.M. is an investigator on vaccine trials sponsored by the GSK group of companies, Pfizer, Sanofi, and Merck. H.S.M.'s, H.M.'s, B.W.'s, M.M.'s and P.H.A.'s institution receives funding for investigator-led studies from industry, including Pfizer and Sanofi Pasteur; H.S.M., H.M., B.W., M.M. and P.H.A. receive no personal payments from industry. D.D.P.-T. and Z.Y.M.Y. declare no conflict of interest.

References

- World Health Organization [WHO]. Tracking SARS-CoV-2 Variants. Available online: https://www.who.int/en/activities/ tracking-SARS-CoV-2-variants/ (accessed on 2 April 2022).
- Pulliam, J.R.C.; van Schalkwyk, C.; Govender, N.; von Gottberg, A.; Cohen, C.; Groome, M.J.; Dushoff, J.; Mlisana, K.; Moultrie, H. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. *medRxiv* 2021. [CrossRef]
- 3. Araf, Y.; Akter, F.; Tang, Y.D.; Fatemi, R.; Parvez, M.S.A.; Zheng, C.; Hossain, M.G. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. *J. Med. Virol.* **2022**, *94*, 1825–1832. [CrossRef] [PubMed]
- Bekliz, M.; Adea, K.; Vetter, P.; Eberhardt, C.S.; Hosszu-Fellous, K.; Vu, D.-L.; Puhach, O.; Essaidi-Laziosi, M.; Waldvogel-Abramowski, S.; Stephan, C.; et al. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. *Nat. Commun.* 2022, *13*, 3840. [CrossRef] [PubMed]
- Cao, Y.; Wang, J.; Jian, F.; Xiao, T.; Song, W.; Yisimayi, A.; Huang, W.; Li, Q.; Wang, P.; An, R.; et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* 2022, 602, 657–663. [CrossRef] [PubMed]
- Sullivan, D.J.; Franchini, M.; Joyner, M.J.; Casadevall, A.; Focosi, D. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. *Nat. Commun.* 2022, 13, 6478. [CrossRef] [PubMed]

- Hansen, C.H.; Schelde, A.B.; Moustsen-Helm, I.R.; Emborg, H.-D.; Krause, T.G.; Mølbak, K.; Valentiner-Branth, P. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. *medRxiv* 2021. [CrossRef]
- Jara, A.; Undurraga, E.A.; Zubizarreta, J.R.; González, C.; Acevedo, J.; Pizarro, A.; Vergara, V.; Soto-Marchant, M.; Gilabert, R.; Flores, J.C.; et al. Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. *Nat. Med.* 2022, *28*, 1377–1380. [CrossRef]
- Kim, S.S.; Chung, J.R.; Talbot, H.K.; Grijalva, C.G.; Wernli, K.J.; Kiniry, E.; Martin, E.T.; Monto, A.S.; Belongia, E.A.; McLean, H.Q.; et al. Effectiveness of 2 and 3 mRNA COVID-19 Vaccines Doses against Omicron and Delta-Related Outpatient Illness among Adults, October 2021–February 2022. medRxiv 2022. [CrossRef]
- 10. Lind, M.L.; Robertson, A.J.; Silva, J.; Warner, F.; Coppi, A.C.; Price, N.; Duckwall, C.; Sosensky, P.; Di Giuseppe, E.C.; Borg, R.; et al. Effectiveness of Primary and Booster COVID-19 mRNA Vaccination against Omicron Variant SARS-CoV-2 Infection in People with a Prior SARS-CoV-2 Infection. *medRxiv* 2022. [CrossRef]
- 11. Powell, A.A.; Kirsebom, F.; Stowe, J.; McOwat, K.; Saliba, V.; Ramsay, M.E.; Lopez-Bernal, J.; Andrews, N.; Ladhani, S.N. Effectiveness of BNT162b2 against COVID-19 in adolescents. *Lancet Infect. Dis.* **2022**, *22*, 581–583. [CrossRef]
- 12. Ng, Q.X.; Lim, S.R.; Yau, C.E.; Liew, T.M. Examining the Prevailing Negative Sentiments Related to COVID-19 Vaccination: Unsupervised Deep Learning of Twitter Posts over a 16 Month Period. *Vaccines* **2022**, *10*, 1457. [CrossRef] [PubMed]
- 13. Garrett, N.; Tapley, A.; Andriesen, J.; Seocharan, I.; Fisher, L.H.; Bunts, L.; Espy, N.; Wallis, C.L.; Randhawa, A.K.; Ketter, N.; et al. High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron. *medRxiv* 2022. [CrossRef]
- Meggiolaro, A.; Schepisi, M.S.; Farina, S.; Castagna, C.; Mammone, A.; Siddu, A.; Stefanelli, P.; Boccia, S.; Rezza, G. Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: A systematic review and meta-analysis. *Expert Rev. Vaccines* 2022, 21, 1831–1841. [CrossRef] [PubMed]
- Mohammed, H.; Yeoh, Z.Y.M.; Nguyen, X.M.; Balanga, L.; Pham-Tran, D.; Marshall, H. A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines. 2021. Available online: https://www.crd.york.ac.uk/prospero/display_ record.php?RecordID=291375 (accessed on 16 March 2022).
- Aromataris, E.; Fernandez, R.; Godfrey, C.M.; Holly, C.; Khalil, H.; Tungpunkom, P. Summarizing systematic reviews: Methodological development, conduct and reporting of an umbrella review approach. *Int. J. Evid. Based Healthc.* 2015, 13, 132–140. [CrossRef] [PubMed]
- 17. Adams, K.; Rhoads, J.P.; Surie, D.; Gaglani, M.; Ginde, A.A.; McNeal, T.; Ghamande, S.; Huynh, D.; Talbot, H.K.; Casey, J.D.; et al. Vaccine effectiveness of primary series and booster doses against omicron variant covid-19-associated hospitalization in the united states. *medRxiv* 2022, 2022.2006.2009.22276228. [CrossRef]
- Altarawneh, H.N.; Chemaitelly, H.; Ayoub, H.H.; Tang, P.; Hasan, M.R.; Yassine, H.M.; Al-Khatib, H.A.; Smatti, M.K.; Coyle, P.; Al-Kanaani, Z.; et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *N. Engl. J. Med.* 2022, 387, 21–34. [CrossRef]
- Buchan, S.A.; Nguyen, L.; Wilson, S.E.; Kitchen, S.A.; Kwong, J.C. Vaccine effectiveness of BNT162b2 against Omicron and Delta outcomes in adolescents. *medRxiv* 2022. [CrossRef]
- Buchan, S.A.; Chung, H.; Brown, K.A.; Austin, P.C.; Fell, D.B.; Gubbay, J.B.; Nasreen, S.; Schwartz, K.L.; Sundaram, M.E.; Tadrous, M.; et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. *medRxiv* 2022. [CrossRef]
- 21. Carazo, S.; Skowronski, D.M.; Brisson, M.; Barkati, S.; Sauvageau, C.; Brousseau, N.; Gilca, R.; Fafard, J.; Talbot, D.; Ouakki, M.; et al. Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination. *medRxiv* 2022. [CrossRef]
- Chemaitelly, H.; Ayoub, H.H.; AlMukdad, S.; Coyle, P.; Tang, P.; Yassine, H.M.; Al-Khatib, H.A.; Smatti, M.K.; Hasan, M.R.; Al-Kanaani, Z.; et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. *Nat. Commun.* 2022, 13, 3082. [CrossRef]
- 23. Collie, S.; Champion, J.; Moultrie, H.; Bekker, L.-G.; Gray, G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. *N. Engl. J. Med.* **2021**, *386*, 494–496. [CrossRef]
- Grewal, R.; Kitchen, S.A.; Nguyen, L.; Buchan, S.A.; Wilson, S.E.; Costa, A.P.; Kwong, J.C. Effectiveness of a fourth dose of COVID-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: Test negative design study. *BMJ* 2022, 378, e071502. [CrossRef]
- 25. Kirsebom, F.; Andrews, N.; Sachdeva, R.; Stowe, J.; Ramsay, M.; Bernal, J.L. Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in England. *medRxiv* 2022. [CrossRef]
- Lauring, A.S.; Tenforde, M.W.; Chappell, J.D.; Gaglani, M.; Ginde, A.A.; McNeal, T.; Ghamande, S.; Douin, D.J.; Talbot, H.K.; Casey, J.D.; et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. *BMJ* 2022, *376*, e069761. [CrossRef] [PubMed]
- Suarez, C.; Milena Khaoua, H.; Courtejoie, N. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. *Eurosurveillance* 2022, 27, 2200250. [CrossRef]

- Tartof, S.Y.; Slezak, J.M.; Puzniak, L.; Hong, V.; Xie, F.; Ackerson, B.K.; Valluri, S.R.; Jodar, L.; McLaughlin, J.M. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: A test-negative case–control study. *Lancet Respir. Med.* 2022, 10, 689–699. [CrossRef]
- Tartof, S.Y.; Slezak, J.M.; Puzniak, L.; Hong, V.; Xie, F.; Ackerson, B.K.; Valluri, S.R.; Jodar, L.; McLaughlin, J.M. BNT162b2 Effectiveness and Durability against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design. SSRN 2022. [CrossRef]
- 30. Thompson, M.G.; Natarajan, K.; Irving, S.A.; Rowley, E.A.; Griggs, E.P.; Gaglani, M.; Klein, N.P.; Grannis, S.J.; DeSilva, M.B.; Stenehjem, E.; et al. Effectiveness of a Third Dose of mRNA Vaccines against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations among Adults During Periods of Delta and Omicron Variant Predominance—VISION Network, 10 States, August 2021–January 2022. MMWR Morb. Mortal. Wkly. Rep. 2022, 71, 139–145. [CrossRef] [PubMed]
- 31. Tseng, H.F.; Ackerson, B.K.; Luo, Y.; Sy, L.S.; Talarico, C.A.; Tian, Y.; Bruxvoort, K.J.; Tubert, J.E.; Florea, A.; Ku, J.H.; et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nat. Med.* **2022**, *28*, 1063–1071. [CrossRef]
- 32. UK Health Security Agency; Andrews, N.; Stowe, J.; Kirsebom, F.; Toffa, S.; Rickeard, T.; Gallagher, E.; Gower, C.; Kall, M.; Groves, N.; et al. COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N. Engl. J. Med.* **2022**, *386*, 1532–1546. [CrossRef]
- UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants under Investigation in England Technical Briefing 34. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/10 50236/technical-briefing-34-14-january-2022.pdf (accessed on 9 July 2022).
- 34. Willett, B.J.; Grove, J.; MacLean, O.A.; Wilkie, C.; Logan, N.; Lorenzo, G.D.; Furnon, W.; Scott, S.; Manali, M.; Szemiel, A.; et al. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. *medRxiv* 2022. [CrossRef]
- Young-Xu, Y.; Zwain, G.M.; Izurieta, H.S.; Korves, C.; Powell, E.I.; Smith, J.; Balajee, A.S.; Holodniy, M.; Beenhouwer, D.O.; Rodriguez-Barradas, M.C.; et al. Effectiveness of mRNA COVID-19 Booster Vaccines against Omicron and Delta Variants among US Veterans. *medRxiv* 2022. [CrossRef]
- Fowlkes, A.L.; Yoon, S.K.; Lutrick, K.; Gwynn, L.; Burns, J.; Grant, L.; Phillips, A.L.; Ellingson, K.; Ferraris, M.V.; LeClair, L.B.; et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection among Children Aged 5–11 Years and Adolescents Aged 12–15 Years—PROTECT Cohort, July 2021–February 2022. *MMWR Morb. Mortal. Wkly. Rep.* 2022, 71, 422–428. [CrossRef] [PubMed]
- 37. Montez-Rath, M.E.; Garcia, P.; Han, J.; Cadden, L.; Hunsader, P.; Morgan, C.; Kerschmann, R.; Beyer, P.; Dittrich, M.; Block, G.A.; et al. SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: The role of circulating receptor-binding domain antibodies and vaccine doses. *medRxiv* 2022. [CrossRef]
- Spensley, K.J.; Gleeson, S.; Martin, P.; Thomson, T.; Clarke, C.L.; Pickard, G.; Thomas, D.; McAdoo, S.P.; Randell, P.; Kelleher, P.; et al. Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. *Kidney Int. Rep.* 2022, 7, 1406–1409. [CrossRef] [PubMed]
- Yoon, S.K.; Hegmann, K.T.; Thiese, M.S.; Burgess, J.L.; Ellingson, K.; Lutrick, K.; Olsho, L.E.W.; Edwards, L.J.; Sokol, B.; Caban-Martinez, A.J.; et al. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. *N. Engl. J. Med.* 2022, 386, 1855–1857. [CrossRef]
- 40. Zou, Y.; Huang, D.; Jiang, Q.; Guo, Y.; Chen, C. The Vaccine Efficacy against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. *Front. Public Health* **2022**, *10*, 940956. [CrossRef]
- Külper-Schiek, W.; Piechotta, V.; Pilic, A.; Batke, M.; Dreveton, L.S.; Geurts, B.; Koch, J.; Köppe, S.; Treskova, M.; Vygen-Bonnet, S.; et al. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. *Front. Immunol.* 2022, 13, 940562. [CrossRef]
- Young-Xu, Y.; Zwain, G.M.; Izurieta, H.S.; Korves, C.; Powell, E.I.; Smith, J.; Balajee, A.; Holodniy, M.; Beenhouwer, D.O.; Rodriguez-Barradas, M.C.; et al. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. *BMJ Open* 2022, *12*, e063935. [CrossRef]
- Arashiro, T.; Arima, Y.; Muraoka, H.; Sato, A.; Oba, K.; Uehara, Y.; Arioka, H.; Yanai, H.; Kuramochi, J.; Ihara, G.; et al. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: A multi-center prospective case-control study (FASCINATE study). *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 2022. [CrossRef]
- 44. Gram, M.A.; Emborg, H.D.; Schelde, A.B.; Friis, N.U.; Nielsen, K.F.; Moustsen-Helms, I.R.; Legarth, R.; Lam, J.U.H.; Chaine, M.; Malik, A.Z.; et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. *PLoS Med.* 2022, 19, e1003992. [CrossRef]
- Ritchie, H.; Ortiz-Ospina, E.; Beltekian, D.; Mathieu, E.; Hasell, J.; Macdonald, B.; Giattino, C.; Roser, M. Our World in Data- Coronavirus (COVID-19) Vaccinations. Available online: https://ourworldindata.org/covid-vaccinations (accessed on 28 November 2022).

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.